×
About 330 results

ALLMedicine™ Waldenstrom Macroglobulinemia Center

Research & Reviews  110 results

Phase I study of Ibrutinib and the CXCR4 antagonist Ulocuplumab in CXCR4 mutated Walden...
https://doi.org/10.1182/blood.2021012953
Blood Treon SPP, Meid KE et. al.

Jul 21st, 2021 - MYD88 and CXCR4 mutations are common in Waldenström Macroglobulinemia (WM). Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a Phase I trial of the CXCR4-antagonist ulocuplumab with ibrutinib in this first-ever study to target...

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290394
Clinical and Experimental Medicine; Gavriatopoulou M, Terpos E et. al.

Jul 20th, 2021 - Vaccination against SARS-CoV-2 is considered as the most important preventive strategy against COVID-19, but its efficacy in patients with hematological malignancies is largely unknown. We investigated the development of neutralizing antibodies (N...

Acrocyanosis and Progressive Skin Necrosis as Manifestation of Waldenstrom Macroglobuli...
https://doi.org/10.1177/15347346211026994
The International Journal of Lower Extremity Wounds; Nekooghadam SM, Bozorgmehr R et. al.

Jun 24th, 2021 - Waldenstrom macroglobulinemia (WM), a rare malignant disorder, occurs as a result of abnormal proliferation of lymphocytes that produce immunoglobulin M. In rare cases, WM complicates by type I cryoglobulinemia. Type I cryoglobulinemia usually pre...

Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection i...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832621
Clinical Lymphoma, Myeloma & Leukemia; Velier M, Priet S et. al.

Feb 10th, 2021 - Severe and Irreversible Pancytopenia Associated With SARS-CoV-2 Bone Marrow Infection in a Patient With Waldenstrom Macroglobulinemia.|2021|Velier M,Priet S,Appay R,Atieh T,Lepidi H,|

see more →

Clinicaltrials.gov  6 results

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicul...
https://clinicaltrials.gov/ct2/show/NCT01381692

May 4th, 2020 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia
https://clinicaltrials.gov/ct2/show/NCT01779167

Jul 10th, 2018 - Waldenstrom macroglobulinemia (WM) is an incurable B-cell lymphoproliferative disorder characterized by expansion of malignant B-lymphocytes and excessive production of monoclonal IgM. The survival and proliferation of the neoplastic WM cells is h...

Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's
https://clinicaltrials.gov/ct2/show/NCT02371148

Apr 8th, 2018 - The progression free survival (PFS) expected for lymphoplasmacytic/lymphoplasmocytoid lymphoma/Waldenstrom macroglobulinemia with the same characteristics indicated into the study and treated with standard Rituximab plus chemotherapy may be estima...

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00711828

Mar 29th, 2018 - PRIMARY OBJECTIVES: I. To assess tumor response to R-CyBor-D in patients with relapsed follicular (Gr 1 or 2), mantle cell, marginal zone lymphomas, small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and lymphoplasmacytic (Waldens...

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
https://clinicaltrials.gov/ct2/show/NCT01177527

Oct 15th, 2017 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...

see more →

News  10 results

Ibrutinib 'Treatment of Choice' in Waldenstrom Macroglobulinemia
https://www.medscape.com/viewarticle/944782

Jan 26th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Change the 'Asymptomatic' Label for Rare Lymphoma Status
https://www.medscape.com/viewarticle/919696

Oct 9th, 2019 - Patients in the early stages of Waldenstrom macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma, are usually followed with observation rather than offered treatment and are labeled "asymptomatic." But this label is inaccurate because many ...

Waldenstrom Macroglobulinemia Clinical Practice Guidelines (2018)
https://reference.medscape.com/viewarticle/905623

Nov 29th, 2018 - The guidelines on the diagnosis, treatment, and follow-up of Waldenstrom macroglobulinemia were released on October 1, 2018, by the European Society for Medical Oncology (ESMO).[1] Diagnosis Waldenstrom macroglobulinemia (WM) is diagnosed based on...

Ibrutinib discontinuation harms survival in CLL
https://www.mdedge.com/hematologynews/nhlhub/article/177618/cll/ibrutinib-discontinuation-harms-survival-cll
Mary Ellen Schneider

Oct 18th, 2018 - Discontinuing ibrutinib therapy because of disease progression was associated with worse survival, according to a real-world study of ibrutinib dosing in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma patients. Courtesy Wikimedia Comm.

Combo treatment under review for Waldenstrom macroglobulinemia
https://www.mdedge.com/hematologynews/nhlhub/article/168936/indolent-lymphoma/combo-treatment-under-review-waldenstrom
Mary Ellen Schneider

Jun 26th, 2018 - Ibrutinib in combination with rituximab as a treatment for Waldenström macroglobulinemia (WM) is under priority review by the Food and Drug Administration. Ibrutinib, a Bruton’s tyrosine kinase inhibitor, is already approved as a single agent for.

see more →

Patient Education  6 results see all →